Ipsen at a glance

Innovation for

patient care

Press releases

03 March 2015

Ipsen’s 2014 results and 2015 financial objectives

02 March 2015

Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

YOU ARE ON IPSEN'S CORPORATE WEBSITE

The corporate website is governed by the International Federation of Pharmaceutical Manufacturers & Associations code of practice.
Certain information provided on this website may not be strictly in conformity with the French regulations on advertising.

> Close